Therion announced that the 255-patient trial did not meet its primary efficacy endpoint of improving overall survival compared with palliative chemotherapy or best supportive care, and said that the company no longer plans to file a biologics license application (BLA) with the FDA for Panvac-VF in pancreatic cancer.
This is the second recent blow for the company, which previously announced disappointing phase II results for Prostvac-VF in men with advanced prostate cancer. The trial did not meet its primary efficacy endpoint of improving progression-free survival. However, preliminary data suggest that Prostvac-VF is associated with a potential reduction in mortality compared to placebo.
Therion also revealed that its investors have identified an investment bank to manage the sale of the company. The sales process will commence immediately and is expected to conclude in several months.